Cargando…

Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease

Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpos...

Descripción completa

Detalles Bibliográficos
Autores principales: De Maré, Annelies, Verhulst, Anja, Cavalier, Etienne, Delanaye, Pierre, Behets, Geert J., Meijers, Bjorn, Kuypers, Dirk, D’Haese, Patrick C., Evenepoel, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947521/
https://www.ncbi.nlm.nih.gov/pubmed/31756992
http://dx.doi.org/10.3390/jcm8122027
_version_ 1783485570669871104
author De Maré, Annelies
Verhulst, Anja
Cavalier, Etienne
Delanaye, Pierre
Behets, Geert J.
Meijers, Bjorn
Kuypers, Dirk
D’Haese, Patrick C.
Evenepoel, Pieter
author_facet De Maré, Annelies
Verhulst, Anja
Cavalier, Etienne
Delanaye, Pierre
Behets, Geert J.
Meijers, Bjorn
Kuypers, Dirk
D’Haese, Patrick C.
Evenepoel, Pieter
author_sort De Maré, Annelies
collection PubMed
description Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpose, in this study we investigate the extent to which circulating sclerostin, skeletal sclerostin expression, bone histomorphometric parameters, and serum markers of bone metabolism associate with each other. Bone biopsies and serum samples were collected in a cohort of 68 end-stage kidney disease (ESKD) patients. Serum sclerostin levels were measured using 4 different commercially available assays. Skeletal sclerostin expression was evaluated on immunohistochemically stained bone sections. Quantitative bone histomorphometry was performed on Goldner stained tissue sections. Different serum markers of bone metabolism were analyzed using in-house techniques or commercially available assays. Despite large inter-assay differences for circulating sclerostin, results obtained with the 4 assays under study closely correlated with each other, whilst moderate significant correlations with skeletal sclerostin expression were also found. Both skeletal and circulating sclerostin negatively correlated with histomorphometric bone and serum parameters reflecting bone formation and turnover. In this study, the unique combined evaluation of bone sclerostin expression, bone histomorphometry, bone biomarkers, and serum sclerostin levels, as assessed by 4 different assays, demonstrated that sclerostin may qualify as a clinically relevant marker of disturbed bone metabolism in ESKD patients.
format Online
Article
Text
id pubmed-6947521
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69475212020-01-13 Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease De Maré, Annelies Verhulst, Anja Cavalier, Etienne Delanaye, Pierre Behets, Geert J. Meijers, Bjorn Kuypers, Dirk D’Haese, Patrick C. Evenepoel, Pieter J Clin Med Article Mounting evidence indicates that sclerostin, a well-known inhibitor of bone formation, may qualify as a clinically relevant biomarker of chronic kidney disease-related mineral and bone disorder (CKD-MBD), including abnormal mineral and bone metabolism and extraskeletal calcification. For this purpose, in this study we investigate the extent to which circulating sclerostin, skeletal sclerostin expression, bone histomorphometric parameters, and serum markers of bone metabolism associate with each other. Bone biopsies and serum samples were collected in a cohort of 68 end-stage kidney disease (ESKD) patients. Serum sclerostin levels were measured using 4 different commercially available assays. Skeletal sclerostin expression was evaluated on immunohistochemically stained bone sections. Quantitative bone histomorphometry was performed on Goldner stained tissue sections. Different serum markers of bone metabolism were analyzed using in-house techniques or commercially available assays. Despite large inter-assay differences for circulating sclerostin, results obtained with the 4 assays under study closely correlated with each other, whilst moderate significant correlations with skeletal sclerostin expression were also found. Both skeletal and circulating sclerostin negatively correlated with histomorphometric bone and serum parameters reflecting bone formation and turnover. In this study, the unique combined evaluation of bone sclerostin expression, bone histomorphometry, bone biomarkers, and serum sclerostin levels, as assessed by 4 different assays, demonstrated that sclerostin may qualify as a clinically relevant marker of disturbed bone metabolism in ESKD patients. MDPI 2019-11-20 /pmc/articles/PMC6947521/ /pubmed/31756992 http://dx.doi.org/10.3390/jcm8122027 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Maré, Annelies
Verhulst, Anja
Cavalier, Etienne
Delanaye, Pierre
Behets, Geert J.
Meijers, Bjorn
Kuypers, Dirk
D’Haese, Patrick C.
Evenepoel, Pieter
Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
title Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
title_full Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
title_fullStr Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
title_full_unstemmed Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
title_short Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease
title_sort clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947521/
https://www.ncbi.nlm.nih.gov/pubmed/31756992
http://dx.doi.org/10.3390/jcm8122027
work_keys_str_mv AT demareannelies clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT verhulstanja clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT cavalieretienne clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT delanayepierre clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT behetsgeertj clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT meijersbjorn clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT kuypersdirk clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT dhaesepatrickc clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease
AT evenepoelpieter clinicalinferenceofserumandbonesclerostinlevelsinpatientswithendstagekidneydisease